ARCHIVES

In Sign-Off Of Two Orphan Drugs, ODAC Leaves Efficacy Interpretation To Docs

This article is from The Cancer Letter archive.

Vol. 24 No. 45 | November 27, 1998

Download PDF Visit The Full Archive

Related Articles

DCT Board Insists On Being Heard In Development Of CCOP Guidelines

February 19, 1982

FDA Advisors Okay DDC For AIDS Treatment In Comb With AZT

May 8, 1992

Scripps, Sandoz Deal Becomes Case Study As NI Rethinks Sponsored Research

January 28, 1994

Senate Emphasizes Balance In NCI’s Research Programs

September 24, 1993

High Radiation Dose Effective Ten Years After Treatment

November 28, 2003

Pfizer Begins Phase III Trial Of Sunitinib In NSCLC

September 28, 2007